Favezelimab Biosimilar - Research Grade

Human

LAG3

>1mg/ml

IgG4 - kappa

CHO Cells

Anti-Mouse LAG-3 (C9B7W) In Vivo Antibody - Low Endotoxin (ICH1078), TSR-033 Biosimilar - Research Grade (ICH5067), Ieramilimab Biosimilar - Research Grade (ICH5098), Relatlimab Biosimilar - Research Grade (ICH5117), Miptenalimab Biosimilar - Research Grade (ICH5259), Encelimab Biosimilar - Research Grade (ICH5524), Fianlimab Biosimilar - Research Grade (ICH5548), Negalstobart Biosimilar - Research Grade (ICH5704), Tuparstobart Biosimilar - Research Grade (ICH5948)

https://www.imgt.org/mAb-DB/

ICH3002

P18627

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of favezelimab, an anti-LAG-3 (lymphocyte-activation gene 3) monoclonal antibody built on a human IgG4-kappa framework and directed against human LAG-3 (UniProt P18627). It is manufactured for research use only and is not the clinical drug, nor is it intended for human or veterinary use. As a research-grade reagent it is well suited to in-vitro and preclinical applications where a defined, sequence-consistent anti-LAG-3 binder is needed: as a positive control or benchmark in binding and blocking assays, as a tool for studying checkpoint biology in reconstituted or cell-based systems, for ADCC/ADC method development, and for characterizing LAG-3 expression and function on T cells. The IgG4 isotype limits effector engagement, consistent with a checkpoint-blocking design. Material is offered at low endotoxin (<1 EU/mg research grade; <0.5 EU/mg ultra-low-endotoxin options) and in bulk milligram-to-gram quantities to support in-vitro standards, assay-scale screening, and preclinical model work. Guidance here is for ichorbio to review and is not a clinical claim. LAG-3 (lymphocyte-activation gene 3; CD223) is a type I transmembrane immune-checkpoint receptor structurally related to CD4, encoded by the LAG3 gene (human UniProt P18627). It is expressed on activated CD4+ and CD8+ T cells, regulatory T cells, NK cells, and subsets of dendritic and B cells, and is a marker of T-cell exhaustion in chronic antigen exposure and tumors. Its best-characterized ligand is MHC class II, to which it binds with higher affinity than CD4; additional reported ligands include FGL1, galectin-3, and LSECtin. Engagement delivers an inhibitory signal that dampens T-cell proliferation, cytokine output, and effector function, and supports regulatory T-cell suppressive activity. Because LAG-3 frequently co-expresses with PD-1, it is a prominent co-inhibitory target, and blocking it can restore anti-tumor T-cell responses, motivating combination checkpoint strategies.

Lymphocyte activation gene 3 protein, FDC

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks